Celldex plans FDA filing for barzolvolimab in 2027; analysts cut price targets
Celldex plans to seek FDA approval for barzolvolimab in chronic spontaneous urticaria in 2027 and is enrolling patients in phase 3 trials for cold urticaria and symptomatic dermographism. Barclays kept its overweight rating on Celldex (CLDX) but cut its price target to $50 from $53. HC Wainwright reiterated its buy rating and lowered its target to $58 from $64, 107.4% above the Nov. 19 close of $27.96.








